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Edited by Jesus AvilaAbstract The bacterial ArsA ATPase is the catalytic compo-
nent of an oxyanion pump that is responsible for resistance to
arsenicals and antimonials. Homologues of the bacterial ArsA
ATPase are widespread in nature. We had earlier identiﬁed the
mouse homologue (Asna1) that exhibits 27% identity to the bac-
terial ArsA ATPase. To identify the physiological role of the
protein, heterozygous Asna1 knockout mice (Asna1+/) were
generated by homologous recombination. The Asna1+/ mice
displayed similar phenotype as the wild-type mice. However,
early embryonic lethality was observed in homozygous Asna1
knockout embryos, between E3.5 (E = embryonic day) and
E8.5 stage. These ﬁndings indicate that Asna1 plays a crucial
role during early embryonic development.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Knockout mouse1. Introduction
The plasmid encoded ArsA ATPase in Escherichia coli is a
component of an ArsAB pump that confers resistance to
arsenicals and antimonials [1]. ArsA is the catalytic subunit
of the pump that hydrolyzes ATP in the presence of arsenite
or antimonite oxyanions. ATP hydrolysis is coupled to extru-
sion of the metalloids through ArsB protein that serves both as
a membrane anchor for ArsA and as an oxyanion transloca-
ting pathway [2].
Genomic sequencing indicates that the homologues of ArsA
are widely distributed in nature and are found in members of
all three domains – prokarya, archaea, and eucarya [3]. We
have identiﬁed the mouse homologue (Asna1) of the bacterial
arsA gene [4]. The Asna1 gene encodes an open reading frame
of 348 amino acids that exhibits 27% identity to E. coli ArsA
ATPase. Asna1 shares 99% identity to its human counterpart
(hASNA-I) and 46% identity to Arr4p from Saccharomyces
cerevisiae [4,5].
Although the bacterial ArsA ATPase has been very well
characterized, the physiological roles of the eukaryotic ArsA*Corresponding author. Fax: +1 313 577 2765.
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doi:10.1016/j.febslet.2006.06.017homologues are not known. The human homologue (hAS-
NA-I) exhibited a low-level of ATPase activity that was stim-
ulated 1.6-fold in the presence of arsenite [6]. The yeast
homologue (Arr4p) exhibited ATPase activity, but the enzyme
was not stimulated by arsenite or any other metals [5]. Disrup-
tion of ARR4 was not lethal but the disrupted strain showed
increased sensitivity to metals at a higher temperature [5,7].
We have proposed that Arr4p is part of a protein complex in-
volved in stress tolerance and not a component of an arsenite
resistance pump [5]. In support of this hypothesis, Arr4p was
recently found in a complex that is involved in protein traﬃck-
ing from Golgi to the endoplasmic reticulum [8].
In an attempt to examine the physiological role of the mam-
malian ArsA homologue, Asna1 null mice were generated by
homologous recombination. While the heterozygous Asna1
knockout mice (Asna1+/) displayed a similar phenotype as
the wild-type, early embryonic lethality was observed in homo-
zygous Asna1 knockout (Asna1/) embryos.2. Materials and methods
2.1. Targeted disruption of mouse Asna1 gene
A 129 SvJ mouse spleen genomic library cloned into the Lambda
FIX II vector (Stratagene) was screened with an Asna1 cDNA probe
spanning the entire reading frame [4]. Selected genomic clones were
further subcloned into pBluescript II KS (+/) phagemid vector
(Stratagene). As shown in Fig. 1A the entire Asna1 gene is present
on an 8.2-kbHindIII genomic fragment. The targeting vector was built
by a multi-step cloning process. A 4.9-kb EcoRI–XhoI genomic frag-
ment in pBluescript vector was digested with XhoI, and the XhoI site
destroyed by ﬁlling in with Klenow fragment. The Asna1 genomic frag-
ment was then released from the plasmid by using its BamHI site. In
the next step, pPNT plasmid (provided by Dr. Richard Mulligan, Har-
vard University) [9] was digested with EcoRI, followed by blunting the
EcoRI site with Klenow fragment. The blunted pPNT plasmid was fur-
ther digested with BamHI, and then ligated to the excised Asna1 frag-
ment, such that the Asna1 fragment resides between the neomycin
resistance and herpes simplex virus-thymidine kinase gene cassettes
(Fig. 1A). Finally, a 3.6-kb EcoRI genomic insert in pBluescript vector
was released by using ﬂanking sites NotI and XhoI in the phagemid
vector. It was then cloned into similarly digested sites of the pPNT
plasmid (Fig. 1A). This replacement introduced new HindIII and XhoI
restriction enzyme sites, which were used to verify targeted clones by
Southern blotting.
The Asna1 targeting vector was linearized with NotI and introduced
into R1 embryonic stem (ES) cells (provided by Dr. Andras Nagy
of Mount Sinai Hospital, Toronto, Canada) [10] by electroporation.
Cells were cultured in the presence of 300 lg/ml G418 and 2 lM
ganciclovir (a gift from Syntex Inc., Palo Alto, CA). Genomic DNAblished by Elsevier B.V. All rights reserved.
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Fig. 1. Targeted disruption of Asna1. (A) Schematic diagram showing the genomic and partial restriction map of the mouse Asna1 locus (top), the
targeting construct (middle), and the predicted structure of the targeted Asna1 locus (bottom). Exons are represented as numbered shaded boxes. The
striped box represents the 5 0 external sequence used as a hybridization probe. neo, neomycin resistance gene cassette; hsv-tk, herpes simplex virus-
thymidine kinase gene cassette. The arrow indicates the direction of transcription of the selection markers. The dotted line on the targeting construct
indicates pBluescript vector derived sequence. Restriction enzyme sites are denoted as follows: B, BamHI; E, EcoRI; H, HindIII; N, NotI; S, SstI; X,
XhoI. Homologous recombination in the region indicated X should result in the targeted Asna1 allele. The approximate sizes of the hybridizing
HindIII, SstI, and XhoI genomic fragments of the wild-type and targeted allele is indicated in a tabular format. (B) Southern blot veriﬁcation of
correctly targeted ES cell clones. Hybridization of HindIII, SstI, and XhoI digested genomic DNA from ES cells probed with a radiolabeled 5 0
external probe reveals the targeting event as a pair of fragment.
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recombination by Southern analysis. A 0.7-kb PCR fragment, 5 0 exter-
nal to the homologous recombination region (Fig. 1A) was generated
using primer pairs 5 0-GGCCAGGATGTTTGCCTG-3 0 and 5 0-GAT-
GATCCAACCCAGGAT-30. The PCR product was gel-puriﬁed,
radiolabeled with [a32P]dATP using the Nick Translation System
(Invitrogen), and used to probe the Southern blots (Fig. 1B).
Clone # 73 containing the targeted Asna1 allele was microinjected
into C57BL/6 blastocysts according to the method described by Brad-
ley [11] and the embryos were subsequently transferred into pseudo-
pregnant foster mother. Five male chimeric mice were obtained from
which two were selected for mating with C57BL/6 females to establish
germ line transmission of the targeted alleles. Genotyping of weanedpups were routinely performed by PCR with two diﬀerent sets of three
primers (Fig. 2). Set 1 included the following: a sense primer AF1 (5 0-
CAGGAGGTCAGATAATGTGTC-3 0) was designed from intron 4
to amplify only the wild-type allele; an antisense primer AR1 (5 0-
CGGGCCTCACACATCTTG-3 0) from exon 6 to amplify both the
wild-type and targeted allele; and a third primer speciﬁc for the neo
gene (N1, 5 0-CGCCTTCTATCGCCTTCTTGACGAGTTCTT-3 0) to
amplify only the targeted allele. Thermal cycling was carried out for
30 cycles: denaturation at 94 C for 45 s, annealing at 55 C for 30 s,
and extension at 72 C for 90 s (Fig. 2B). Set 2 included the following
primers: a sense primer AF2 (5 0-CCCAGCAAGGTGGCAAATCT-
3 0) was designed from intron 4 to amplify only the wild-type allele;
an antisense primer AR2 (5 0-GCTGATCCTGGGGCTTTCAG-3 0)
Fig. 2. PCR analysis of F2 mice. (A) Scheme for PCR detection of wild-type and disrupted Asna1 alleles. The exons are indicated as numbered
shaded boxes while the block arrow represents the neomycin (neo) resistance gene cassette. The asterisk (*) indicates a truncated exon. The location of
primers AF1, AF2, AR1, AR2, N1, and N2 are depicted. (B) PCR analysis of F2 Asna1+/ intercrosses and electrophoresed on 1.5% agarose gel. ‘1’
represents a 552-bp PCR product obtained using primer pairs AF1 and AR1 to detect the wild-type allele; ‘2’ represents a 675-bp PCR product
obtained using primer pairs N1 and AR1 to detect the targeted allele. (C) A second set of PCR analysis using separate set of primers was also
performed on F2 mice and resolved on 0.9% agarose gel. ‘3’ represents a 5371-bp PCR product obtained using primer pairs AF2 and AR2 for the
wild-type allele; ‘4’ represents a 5693-bp PCR product obtained using primer pairs N2 and AR2 for the targeted allele. +/+ and +/ represent wild-
type and Asna1+/ mice, respectively.
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targeted allele; and a third primer speciﬁc for the neo gene (N2, 5 0-
CTGACCGCTTCCTCGTGCTT-3 0) to amplify only the targeted al-lele. PCR was performed for 30 cycles under the following set of con-
ditions: denaturation at 95 C for 30 s, annealing at 65 C for 30 s, and
extension at 72 C for 6 min (Fig. 2C).
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Asna1+/ mice were mated and monitored daily for plugs. Females
with copulation plugs were considered to be at day 0.5 of gestation.
Pregnant females were sacriﬁced at diﬀerent times of gestation, and
the embryos were dissected free of maternal tissues and genotyped
by PCR. For genotyping of blastocysts, the blastocysts were ﬂushed
from the uteri at 3.5 days post coitum, lysed individually, and then
subjected to multiplex PCR using Set 1 primers.
2.3. Northern blot analysis
Total RNA was isolated from several organs of wild-type (Asna1+/+)
and Asna1+/ mice at 10 weeks of age using RNeasy Protect Mini Kit
(Qiagen). For Northern blot analysis, 5–10 lg of either Asna1+/+ or
Asna1+/ total RNA was size fractionated on a 1% formaldehyde/aga-
rose gel and transferred to a nylon membrane. cDNA-fragment for
mouse Asna1 was ampliﬁed by PCR using sense primer 5 0-GGGTT-
GAAGCAGAAGAGTTCGAGGATG-3 0 and antisense primer
5 0-GTATGGCCGGTGGGTGCTGTGTCGAAC-3 0, gel puriﬁed,
radiolabeled with [a32P]dATP, and used to probe the Northern blots.
The same ﬁlter was hybridized with a b-actin probe to correct for load-
ing of mRNA. The band intensity in each lane was quantitated and
normalized against b-actin using the UN-SCAN-IT gel software (Silk
Scientiﬁc).Brain Heart Liver Kidney
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Fig. 3. Northern blot analysis of total cellular RNA from organs of
wild-type and heterozygous Asna1 knockout mice. (A) Equal amounts
of total RNA from organs of wild-type or Asna1+/ mice were
separated on a 1% formaldehyde/agarose gel for blot analysis. The
RNA blot ﬁlter was hybridized with a mouse Asna1 cDNA probe. (B)
The same ﬁlter was then re-hybridized with a mouse b-actin probe. +/+
and +/ represent wild-type and Asna1+/ mice, respectively. (C) The
Asna1 and b-actin band intensity in each lane was quantitated by
densitometric scanning and normalized against b-actin. The Asna1
mRNA isolated from the organs of Asna1+/ knockout mice was then
compared with that of wild-type. The error bars represent standard
error for three separate sets of Northern experiments.3. Results
3.1. Targeted disruption of the mouse Asna1 gene
To disrupt the Asna1 gene, a targeting vector was con-
structed in which a 2.5 kb EcoRI fragment containing exons
3, 4, 5, and part of exon 6 was replaced with a 1.9-kb neomycin
resistance cassette (Fig. 1A). The targeting vector was intro-
duced into R1 ES cells by electroporation. Forty-six homolo-
gous recombinants were identiﬁed by Southern analysis
(Fig. 1B) out of 290 G418-resistant clones. Recombinant cells
were injected into the blastocysts of C57BL/6 mice, resulting in
the generation of male chimeric mice. F1 heterozygotes were
generated by mating the chimeras with C57BL/6 females.
The F2 progeny from heterozygous intercrosses were geno-
typed by PCR (Fig. 2).
3.2. Phenotype of Asna1+/ mice
Asna1+/ mice were found to be healthy and fertile. There
was apparently no gender bias, male and female population
being present in equal frequency (Table 1). Heterozygous
Asna1 knockout mice showed no observable diﬀerence in
appearance, body weight, behavior, or organ size. There was
no development of tumor or other abnormalities over a time
course of six months. Northern blot analysis was performed
to determine the levels of Asna1 mRNA in diﬀerent organs
of Asna1+/+ and Asna1+/ mice. Fig. 3 shows that the levelsTable 1
Genotypes of live births and embryos from Asna1+/ mating
Stage Genotype
+/+ +/ /
Four weeks 219 425 0
Male 108 217 0
Female 111 208 0
E14.5 4 10 0
E11.5 3 7 0
E10.5 4 9 0
E9.5 8 12 0
E8.5 4 9 0
E3.5 2 3 3of Asna1 mRNA in organs, such as brain, heart, liver, and
kidney in Asna1+/ mice were at 40–60% of those in the
Asna1+/+ mice. This suggests that one normal allele of the
Asna1 gene is suﬃcient to maintain the level of Asna1 protein
necessary for its cellular activity.
3.3. Embryonic lethality of Asna1/ mice
Heterozygous animals were intercrossed and their oﬀspring
genotyped by PCR analysis (Fig. 2). A total of 644 mice were
genotyped, of which 219 were wild-type, and 425 were hetero-
zygous for the Asna1 locus (Table 1). No homozygous mutants
were recovered at birth. These genotypes were conﬁrmed by
two independent primer sets as shown in Fig. 2. The absence
of any homozygous mutant, along with generation of wild-
type and heterozygous progeny at a 1:2 ratio, indicates that
Fig. 4. PCR analysis of E3.5 embryos. Multiplex PCR using Set 1
primers (see Section 2) were performed on blastocysts, which were
derived from Asna1+/ intercrosses, and electrophoresed on 1.5%
agarose gel. +/+, +/, and / represent wild-type, Asna1+/, and
Asna1/ embryos, respectively.
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the time of embryonic lethality, embryos were collected from
heterozygous intercrosses at diﬀerent days of gestation. None
of the E8.5 (E = embryonic day), E9.5, E10.5, E11.5, and
E14.5 embryos genotyped were Asna1/ (Table 1). However,
empty decidua which could account for the resorption of
Asna1/ embryos was found at E8.5–E9.5 (data not shown).
To determine whether the Asna1/ embryos die during preim-
plantation stages, E3.5 blastocysts were isolated and geno-
typed by PCR (Fig. 4). The blastocysts were normal in
appearance and did not show any morphological irregularities.
At E3.5, Asna1/ embryos could be detected by PCR analy-
sis. These results indicate that Asna1/ embryos die within
E3.5 and E8.5 stage. These results are consistent with a role
of Asna1 in early embryonic development.4. Discussion
The mouse Asna1 protein is the bacterial homologue of a
plasmid encoded ArsA ATPase. BLAST search using mouse
Asna1 as the query sequence shows 134 bacterial, 12 archaea,
and 49 eukaryotic homologues. The E. coli homologue (ArsA)
has been extensively studied [12]. ArsA hydrolyzes ATP in the
presence of arsenite, and is the catalytic component of an
oxyanion pump that provides resistance to arsenicals. Leipe
et al. [13] have suggested that Asna1 homologues are most
likely of archaeal or archaeoeukaryotic origin, and have spread
to bacteria only recently to provide selective environmental
advantage.
The yeast homologue (Arr4p) exhibits 46% identity to
Asna1. ARR4 has been disrupted in S. cerevisiae and the null
mutant has been reported to have no growth defects either on
synthetic complete media or on rich media [7]. However, the
disrupted strain shows increased sensitivity to heavy metals
and temperature, indicating that Arr4p may be part of a com-
plex that is involved in stress tolerance [5]. Schuldiner et al. [8]
have reported that Arr4p (renamed as Get3p) is a subunit ofthe GET complex. The GET complex has been shown to be re-
quired for the ATP-dependent retrieval of proteins that con-
tain the HDEL signal from the Golgi to the endoplasmic
reticulum in an ERD2 dependent manner. The other compo-
nents of the GET complex are Mdm39p (Get1p) that was sug-
gested to be involved in mitochondrion biogenesis [14], and
Rmd7p (Get2p), which was proposed to play a role in cell wall
organization [15,16]. Either GET1 or GET2 deletion strains of
S. cerevisiae are viable [17]. Mammalian homologues of these
two proteins have not yet been identiﬁed.
More recently, Metz et al. [18] have demonstrated the copper
dependent binding of Arr4p (Get3p) to the yeast intracellular
CLC chloride-transport protein, Gef1p. Gef1p has been shown
to play a role in copper metabolism and iron transport [19,20].
Since Arr4p is a negative regulator of Gef1p activity, it was
suggested that Arr4p is involved in copper transport, and its
mammalian counterpart was postulated to play a similar role
in mammalian copper metabolism [18]. The mammalian
homologues of Gef1p, Clcn-3, -4, and -5, exhibit chloride/pro-
ton exchange activity, and have been studied in greater detail
[21]. Homozygous Clcn3 knockout mice are viable at birth,
but show increased neurological and developmental defects,
and higher mortality [22]. Homozygous Clcn5 knockout mice
are viable but show increased renal problems and spinal
abnormalities [23].
Although the human homologue (hASNA-I) has been sug-
gested to have arsenite-stimulated ATPase activity [6], we have
been unable to replicate these results with puriﬁed mouse en-
zyme (data not shown), and consider it unlikely that this en-
zyme is a component of an arsenite pump in mammals. To
examine whether protein traﬃcking, copper transport, or some
other function is the major physiological role of Asna1; we
generated a null mutation of the Asna1 gene by homologous
recombination in mouse ES cells. Asna1+/ mice with one nor-
mal allele show no apparent abnormalities in development or
fertility, indicating that one functional copy of the gene is suf-
ﬁcient for normal development. Interbreeding of the Asna1+/
mice failed to generate any homozygous Asna1 knockouts sug-
gesting an embryonic lethal phenotype. Asna1/ embryos
could be recovered at the blastocyst (E3.5) stage, but not at
E8.5, indicating that Asna1 activity plays an important role
in early embryogenesis. It is unlikely that any human disease
will be linked to deletions in Asna1, which would result in loss
of Asna1 activity, since such a situation would lead to death in
utero. However, it is possible that missense mutations that lead
to a less severe disease may yet be identiﬁed. Further studies to
identify the role of Asna1 would require the development of
conditional knockout mouse.
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